Filtered By:
Source: EuroIntervention
Condition: Bleeding
This page shows you your search results in order of date.
Order by Relevance | Date
Total 113 results found since Jan 2013.
De-escalation from ticagrelor to clopidogrel in patients with acute myocardial infarction: the TALOS-AMI HBR substudy
CONCLUSIONS: In stabilised acute myocardial infarction patients, unguided de-escalation from ticagrelor to clopidogrel was associated with a lower rate of net adverse clinical outcomes irrespective of HBR status. The effect of de-escalation of P2Y12 inhibition on reducing haemorrhagic events was greater in patients with HBR.PMID:37724337 | DOI:10.4244/EIJ-D-23-00427
Source: EuroIntervention - September 19, 2023 Category: Cardiovascular & Thoracic Surgery Authors: Min Chul Kim Sung Gyun Ahn Kyung Hoon Cho Doo Sun Sim Young Joon Hong Ju Han Kim Myung Ho Jeong Jun-Won Lee Young-Jin Youn Hee-Yeol Kim Ki-Dong Yoo Doo-Soo Jeon Eun-Seok Shin Young-Hoon Jeong Kiyuk Chang Youngkeun Ahn Source Type: research
Periprocedural continuation versus interruption of oral anticoagulant drugs during transcatheter aortic valve implantation: rationale and design of the POPular PAUSE TAVI trial
EuroIntervention. 2023 Aug 22:EIJ-D-23-00206. doi: 10.4244/EIJ-D-23-00206. Online ahead of print.ABSTRACTAbout one-third of patients undergoing transcatheter aortic valve implantation (TAVI) use oral anticoagulants (OAC), mainly due to atrial fibrillation. General guidelines advise interrupting OAC in patients with a high risk of bleeding undergoing interventions. However, preliminary observational data suggest that the continuation of OAC during TAVI is safe and may reduce the risk of periprocedural thromboembolic events. The Periprocedural Continuation Versus Interruption of Oral Anticoagulant Drugs During Transcatheter ...
Source: EuroIntervention - August 22, 2023 Category: Cardiovascular & Thoracic Surgery Authors: Dirk-Jan van Ginkel Willem L Bor Christophe L F Dubois Hugo M Aarts Maxim J P Rooijakkers Kees H van Bergeijk Liesbeth Rosseel Leo Veenstra Ole De Backer Nicolas M Van Mieghem Frank van der Kley Adriaan Wilgenhof Remigio Leonora Jonathan Halim Carl E Scho Source Type: research
Three-year outcomes of A Randomized Multicentre Trial Comparing Revascularization and Optimal Medical Therapy for Chronic Total Coronary Occlusions (EuroCTO)
CONCLUSIONS: At 3 years there was no difference in the rate of cardiovascular death or myocardial infarction between PCI or OMT among patients with a remaining single coronary CTO. The MACE rate was higher in the OMT group due largely to ischaemia-driven revascularisation. CTO PCI appears to be a safe option for patients with a single remaining significant coronary CTO. CinicalTrials.gov: NCT01760083.PMID:37482940 | DOI:10.4244/EIJ-D-23-00312
Source: EuroIntervention - July 24, 2023 Category: Cardiovascular & Thoracic Surgery Authors: Gerald S Werner David Hildick-Smith Victoria Martin Yuste Nicolas Boudou Georgios Sianos Valery Gelev Jose Ramon Rumoroso Andrejs Erglis Evald Hoj Christiansen Javier Escaned Carlo di Mario Luis Teruel Alexander Bufe Bernward Lauer Alfredo Ruggero Galassi Source Type: research
Early safety and feasibility of a first-in-class biomimetic transcatheter aortic valve - DurAVR
CONCLUSIONS: Preliminary results from the FIH study with DurAVR THV demonstrate a good safety profile with promising haemodynamic performance sustained at 1 year and restoration of near-normal flow dynamics. Further clinical investigation is warranted to evaluate how DurAVR THV may play a role in addressing the challenge of lifetime management in AS patients.PMID:37334801 | DOI:10.4244/EIJ-D-23-00282
Source: EuroIntervention - June 19, 2023 Category: Cardiovascular & Thoracic Surgery Authors: Susheel K Kodali Paul Sorajja Christopher U Meduri Kari Feldt Jo ão L Cavalcante Pankaj Garg Nadira Hamid Karl K Poon Magnus R M Settergren Marcus R Burns Andreas R ück Janarthanan Sathananthan Alan Zajarias Tamaz Shaburishvili Teona Zirakashvili Maia Z Source Type: research
P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients with acute coronary syndromes undergoing coronary stenting: rationale and design of the NEOMINDSET Trial
EuroIntervention. 2023 Jun 12:EIJ-D-23-00125. doi: 10.4244/EIJ-D-23-00125. Online ahead of print.ABSTRACTDual antiplatelet therapy (DAPT) is currently the standard of care after percutaneous coronary intervention (PCI). Recent studies suggest that reducing DAPT to 1-3 months followed by an aspirin-free single antiplatelet therapy (SAPT) strategy with a potent P2Y12 inhibitor is safe and associated with less bleeding. However, to date, no randomised trial has tested the impact of initiating SAPT immediately after PCI, particularly in patients with acute coronary syndromes (ACS). NEOMINDSET is a multicentre, randomised, open...
Source: EuroIntervention - June 12, 2023 Category: Cardiovascular & Thoracic Surgery Authors: Patricia O Guimar ães Marcelo Franken Caio A M Tavares Fabio S Silveira Murillo O Antunes Ricardo R Bergo Rodrigo M Joaquim Jessica C S Hirai Pedro B Andrade Fabio G Pitta Jos é Mariani Bruno R Nascimento Jo ão E T de Paula Marcos S Silveira Tiberio A Source Type: research
Thirty-day and one-year outcomes of the Navitor transcatheter heart valve in patients with aortic stenosis: the prospective, multicentre, global PORTICO NG Study
CONCLUSIONS: The PORTICO NG Study demonstrates low rates of adverse events and PVL up to 1 year in patients at high or extreme surgical risk, confirming the safety and efficacy of the Navitor THV system.PMID:36895190 | DOI:10.4244/EIJ-D-22-01108
Source: EuroIntervention - March 10, 2023 Category: Cardiovascular & Thoracic Surgery Authors: Lars Sondergaard Antony S Walton Stephen G Worthley Dave Smith Bassem Chehab Ganesh Manoharan Gerald Yong Francesco Bedogni Nicholas Bates Michael J Reardon Source Type: research
